




The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 3.8% points. The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 173% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 122% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	350,051
Cost of Goods Sold	0
Intangible Assets	76,501
Liabilities, Current	61,246
Liabilities, Non-Current	9,740
Other Assets	4,173
Other Compr. Net Income	-603
Other Expenses	34,608
Other Liabilities	424,646
Other Net Income	-51,300
Other Revenues	230,784
Property and Equipment	71,336
Research and Development	182,787
Selling, General and Administrative Expense	43,266

Output Variable	Value in 1000 USD
Assets	502,061
Liabilities	495,632
Expenses	260,661
Revenues	230,784
Stockholders Equity	6,429
Net Income	-81,177
Comprehensive Net Income	-81,478
BaseVar	770,520
ECR before LimitedLiability	-14%
Economic Capital Ratio	141%